oxalates and Pain

To examine the relationship between dietary oxalates and the development of vulvodynia.. We conducted a population-based, case-control study of women with and without vulvodynia from 9 ethnically diverse Boston-area communities. Conditional logistic regression analyses were used to estimate the odds of developing vulvodynia as a consequence of self-reported consumption patterns of high-oxalate foods and total weekly dietary oxalate. Oxalate consumption was referenced prior to the onset of symptoms in cases and to a matched reference date among controls.. Baseline clinical characteristics were similar among the 242 cases and 242 controls except for a higher reported incidence of pain/difficulty with first tampon insertion among cases (46.3% vs. 32.2%, p < 0.01). After adjusting for potential confounders, no differences were observed in consumption patterns of different high-oxalate foods between cases and controls, and there was no increase in risk of developing vulvodynia with increasing tertiles of estimated oxalate intake. In addition, we saw no association between increasing consumption of various food items high in oxalate content and the risk of vulvodynia.. Dietary oxalate consumption does not appear to be associated with an elevated risk of vulvodynia.

Topics: Adult; Case-Control Studies; Diet; Female; Humans; Middle Aged; Oxalates; Pain; Risk Factors; Surveys and Questionnaires; Vulvar Diseases

The etiology of localized provoked vulvodynia (LPV) remains unknown, but observations suggest the involvement of the vaginal microbiota. We examined the vaginal microbiota of women with LPV and healthy controls, upon after a low-oxalate diet (LOD).. A total of 9 women diagnosed with secondary LPV and 21 healthy controls were recruited from the Galilee Medical Center in Israel and subjected to prospective evaluations of their vaginal microbiota. Total DNA was extracted from vaginal discharge samples provided before and after following LOD for 3 weeks and was then subjected to 16S sequencing. Data obtained were then used to evaluate α and β diversity, identify differentially abundant bacterial taxa in LPV, and determine their impact on the metabolism.. These evaluations revealed decreased diversity in the vaginal microbiota of women with LPV and identified the Ochrobactrum genus and Pseudomonadaceae family as indicators for LPV. In addition, we identified 23 differentially expressed bacterial metabolic pathways between the LPV and control samples and revealed that LOD could induce changes in the β diversity of LPV vaginal microbiomes, which was further supported by some degree of pain reduction in patients.. Localized provoked vulvodynia and LOD were associated with shifts in the vaginal microbiota. However, the impact of these changes on the development of LPV requires additional studies with a larger cohort.

Topics: Bacteria; Female; Humans; Microbiota; Oxalates; Pain; Vagina; Vulvodynia

A series of substituted N-methylisonicotinamidine (2a-f), N-methylpyrazine-2-carboxamidine (2g-i) derivatives were synthesized by reaction of amidine derivatives (1a-i) with methyl iodide in presence of triethylamine. Five-membered condensed dihydroimidazolylbenzenesulfonamide derivatives (3a-i) were obtained by the reaction of amidine derivatives (1a-i) with acylating agent oxalyl chloride. All the compounds, i.e. 2a-i and 3a-i were purified by crystallization. Structures of all the synthesized compounds are supported by correct IR, (1)H NMR, mass spectral and analytical data. Anti-inflammatory activity evaluation was carried out using carrageenan-induced paw oedema assay and compounds 2e, 3a and 3d exhibited good anti-inflammatory activity (44%, 31% and 37% activity at 50 mg/kg p.o., respectively). Analgesic activity evaluation was carried out using acetic acid writhing assay and compounds 2a and 3f gave 75% activity each at 100 mg/kg p.o.; on the other hand compounds 3a and 3d exhibited 60% analgesic activity each at 50 mg/kg p.o. Compounds 3a and 3d exhibited good anti-inflammatory and analgesic activities.

Topics: Administration, Oral; Amidines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chlorides; Crystallography, X-Ray; Cyclization; Disease Models, Animal; Drug Evaluation, Preclinical; Edema; Female; Male; Mice; Models, Molecular; Molecular Structure; Oxalates; Pain; Pain Measurement; Rats; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship

This study was undertaken to determine the urinary oxalate excretion patterns in patients with vulvodynia compared with controls and to evaluate antioxalate therapy in women with vulvar pain syndrome (vulvodynia).. A total of 130 consecutive patients with vulvar pain syndrome and 23 volunteers without symptoms collected urine specimens for 24 hours; each voiding was saved in individual labeled containers and refrigerated. The specimens were analyzed individually for oxalate and calculated according to 24-hour concentration, volume, and peak oxalate by hour. A total of 59 patients were treated with low-oxalate diets and calcium citrate for 3 months and evaluated for objective relief of vulvar pain.. The 24-hour excretion of oxalate was almost identical in controls and vulvodynia patients. The total 24-hour excretion was directly proportional to the volume of urine excreted (p < 0.001). No significant differences were found in peak oxalate excretion (95% confidence intervals). The number of voidings was higher in the vulvodynia cohort (p < 0.02). The 59 women with elevated oxalate concentrations (> 1 mg/40 dl) were treated with an antioxalate regimen. Fourteen (24%) demonstrated an objective response, but only 6 (10%) could have pain-free sexual intercourse.. Urinary oxalates may be nonspecific irritants that aggravate vulvodynia; however, the role of oxalates as instigators is doubtful.

Topics: Circadian Rhythm; Cohort Studies; Female; Humans; Oxalates; Pain; Prospective Studies; Syndrome; Vulvar Diseases

An extension of the "squirming test" is described which makes the method specific for nonnarcotic analgesics. The intraperitoneal injection of acetic acid causes squirming and an increase in capillary permeability that is measured by direct estimation of plasma-bound dye (Pontamine Sky Blue) which has leaked into the peritoneal cavity. Nonnarcotic analgesics inhibit squirming and leakage of dye. Values for the oral ED50s for both effects are given for a number of typical compounds. Narcotic analgesics, in doses that produce analgesia, inhibit squirming but do not significantly affect leakage of dye. Drugs that stimulate the central nervous system and also inhibit squirming have no significant effect on leakage of dye over the range of doses which inhibit squirming. Corticosteroids do not significantly inhibit either squirming or leakage of dye.

Topics: Acetates; Amphetamine; Analgesics, Non-Narcotic; Animals; Antipyretics; Aspirin; Capillary Permeability; Coloring Agents; Cortisone; Ephedrine; Hydrazines; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Mice; Narcotics; Oxalates; Pain; Paramethasone; Peritoneal Cavity; Pharmacology; Research; Sympathomimetics